background
preliminari
result
suggest
pertussi
infect
might
consid
infant
season
respiratori
syncyti
viru
rsv
outbreak
method
order
analyz
clinic
featur
laboratori
find
infant
pertussi
hospit
acut
respiratori
symptom
season
rsv
outbreak
conduct
retrospect
singlecent
studi
infant
pertussi
boy
median
age
day
match
control
rsvbronchiol
hospit
octob
april
b
pertussi
rsv
detect
nasopharyng
wash
real
timepcr
result
infant
pertussi
less
often
breastfe
infant
rsv
bronchiol
vs
p
clinic
significantli
fewer
infant
pertussi
control
episod
whoop
cough
vs
p
also
less
frequent
fever
admiss
vs
p
apnea
vs
p
cyanosi
vs
p
infant
pertussi
often
abnorm
chest
sound
auscult
infant
rsv
bronchiol
vs
p
absolut
blood
lymphocyt
eosinophil
count
higher
infant
b
pertussi
control
bronchiol
vs
cellsmm
p
vs
cellsmm
p
molecular
analysi
b
pertussi
isol
gene
show
presenc
gene
variant
conclus
infant
hospit
acut
respiratori
symptom
physician
suspect
pertussi
infect
seek
specif
clinic
symptom
investig
lymphocyt
eosinophil
count
thu
diagnos
infect
earli
enough
allow
treatment
pertussi
major
public
health
problem
affect
adolesc
adult
well
children
despit
widespread
vaccin
program
past
fifteen
year
seen
return
pertussi
worldwid
pertussi
resurg
europ
attribut
incomplet
immun
program
genet
chang
bordetella
pertussi
b
pertussi
current
use
acellular
pertussi
vaccin
contain
pertactin
gene
variant
pertussi
toxinb
subunit
molecular
chang
two
gene
past
year
suggest
antigen
diverg
may
make
pertussi
vaccin
less
effect
countri
pertussi
immun
mandatori
other
vaccin
schedul
suggest
first
dose
given
age
month
henc
infant
remain
unimmun
incomplet
immun
incomplet
immun
pertussi
may
develop
atyp
clinic
form
difficult
diagnos
pertussi
especi
difficult
diagnos
children
year
age
winter
season
pathogen
respiratori
syncyti
viru
rsv
circul
difficult
case
pertussi
acut
respiratori
symptom
overlap
bronchiol
studi
conduct
group
infant
hospit
rsv
bronchiol
show
almost
patient
coinfect
b
pertussi
sinc
b
pertussisrsv
coinfect
infrequ
young
infant
physician
keep
possibl
coinfect
mind
diagnos
earli
prevent
bronchiol
becom
sever
although
standard
diagnost
criterion
identifi
b
pertussi
cultur
obtain
nasal
swab
nasopharyng
aspir
confirmatori
inform
come
nowday
molecular
techniqu
real
timepolymeras
chain
reaction
rtpcr
usual
clinic
practic
diagnosi
gener
reach
without
microbiolog
confirm
conspicu
lack
clinician
awar
clinic
laboratori
data
need
reach
suspect
b
pertussi
diagnosi
order
start
treatment
earli
main
purpos
retrospect
singlecent
studi
describ
compar
clinic
laboratori
featur
infant
pertussi
infect
infant
hospit
rsv
bronchiol
analyz
genet
characterist
b
pertussi
retrospect
singlecent
studi
group
infant
hospit
octob
april
pediatr
emerg
depart
acut
respiratori
symptom
select
studi
consecut
infant
age
less
month
boy
median
age
day
rang
real
timepcr
confirm
pertussi
also
analyz
data
b
pertussi
variant
among
hospit
patient
b
pertussi
cultur
control
group
recruit
ageand
sexmatch
infant
boy
median
age
day
rang
infant
hospit
period
rtpcr
confirm
rsv
bronchiol
neg
b
pertussi
diagnosi
bronchiol
consid
infant
less
month
first
episod
acut
infect
lower
respiratori
tract
infant
comorbid
exclud
detail
demograph
clinic
laboratori
data
obtain
patient
parent
structur
questionnair
medic
file
clinic
outcom
variabl
evalu
includ
gender
gestat
age
birth
weight
type
deliveri
dtap
diphtheria
tetanu
acellular
pertussi
vaccin
receiv
breast
feed
histori
age
weight
admiss
number
sibl
sibl
school
cough
admiss
presenc
durat
paroxysm
cough
presenc
fever
bodi
temperatur
apnea
cyanosi
chest
sound
hospit
day
laboratori
outcom
variabl
investig
white
bloodcel
count
wbc
lymphocyt
count
eosinophil
count
neutrophil
count
platelet
count
hemoglobin
hb
glutam
oxaloacet
transaminas
sgot
glutam
pyruv
transaminas
sgpt
gammaglutamyl
transferas
ggt
creactiv
protein
crp
hospit
admiss
infant
assign
clinic
sever
score
rang
accord
respiratori
rate
arteri
oxygen
satur
room
air
retract
none
present
present
nasal
flare
abil
feed
normal
reduc
intraven
fluid
replac
infant
parent
ask
particip
studi
gave
written
inform
consent
studi
approv
policlinico
umberto
institut
review
board
refer
day
hospit
infant
underw
nasal
pharyng
wash
ml
steril
salin
inject
nostril
collect
syring
sampl
deliv
room
temperatur
within
hour
depart
infecti
parasit
immunemedi
diseas
istituto
superior
di
rome
identifi
b
pertussi
molecular
medicin
depart
sapienza
univers
rome
virolog
laboratori
identifi
rsv
pertussi
diagnos
use
insert
sequenc
ptxp
gene
target
gene
realtimepcr
sybr
green
detect
assay
perform
use
lightcycl
roch
diagnost
data
analyz
lightcycl
softwar
version
roch
diagnost
sampl
test
posit
b
pertussi
confirm
bordetella
real
time
pcr
kit
diagenod
belgium
specif
primer
probe
detect
b
pertussi
dna
commerciallyavail
pcr
kit
diagenod
belgium
select
literatur
b
pertussi
isol
cultur
charcoal
agar
plate
oxoid
england
contain
defibrin
sheep
blood
incub
day
inspect
daili
isol
store
medium
contain
brain
heart
infus
bhi
oxoid
england
supplement
glycerol
chromosom
dna
b
pertussi
strain
extract
use
qiaamp
dna
minikit
qiagen
hilden
germani
obtain
gene
molecular
sequenc
data
pertussi
toxin
subunit
ptxa
pertussi
toxin
promot
ptxp
pertactin
prn
sequenc
analyz
two
b
pertussi
clinic
isol
use
primer
describ
previous
amplif
done
mastercycl
person
thermal
cycler
eppendorff
hamburg
germani
ptxa
ptxp
prn
amplifi
contain
pcr
buffer
contain
mm
mgcl
mm
mgso
mm
deoxynucleotid
dntp
finnzym
finlandia
pmol
primer
u
hotstartaq
qiagen
hilden
germania
dimethyl
sulfoxid
ad
also
prn
gene
ptxa
ptxp
gene
amplifi
cycl
ptxa
ptxp
prn
gene
cycl
min
amplif
product
analyz
electrophoresi
purifi
qiaquick
purif
column
kit
qiagen
subsequ
sequenc
analysi
sequenc
analyz
blast
program
amino
acid
sequenc
result
nucleotid
sequenc
compar
use
dnaman
program
version
upon
arriv
virolog
laboratori
nasal
wash
centrifug
remov
mucu
present
sampl
divid
two
aliquot
first
aliquot
use
nucleic
acid
extract
use
total
nucleic
acid
isol
kit
roch
diagnost
mannheim
germani
rtpcr
panel
sought
rsv
respiratori
virus
influenza
b
virus
human
coronaviru
adenoviru
parainfluenza
viru
humanmetapneumoviru
humanbocaviru
rhinoviru
data
analyz
use
spss
program
version
data
report
median
rang
mean
standard
deviat
percentag
categor
variabl
analyz
pearson
chisquar
test
fisher
test
continu
variabl
mannwhitney
u
test
p
valu
consid
indic
statist
signific
b
pertussi
cluster
observ
studi
signific
differ
found
infant
confirm
b
pertussi
control
infant
rsvbronchiol
demograph
characterist
includ
gender
gestat
age
birth
weight
type
deliveri
dtap
vaccin
statu
age
admiss
weight
admiss
presenc
sibl
school
percentag
infant
breast
fed
hospit
lower
group
infant
b
pertussi
one
rsv
bronchiol
vs
p
tabl
data
clinic
characterist
show
percentag
infant
paroxysm
cough
significantli
higher
cough
admiss
last
longer
infant
pertussi
control
infant
vs
p
day
vs
day
p
percentag
infant
fever
tc
significantli
lower
infant
pertussi
control
group
vs
p
percentag
infant
apnea
cyanosi
significantli
higher
infant
pertussi
rsv
bronchiol
apnea
vs
p
cyanosi
vs
p
final
infant
pertussi
less
often
abnorm
chest
sound
auscult
infant
rsv
bronchiol
vs
p
signific
differ
found
two
group
regard
clinic
sever
score
median
rang
vs
day
hospit
vs
clinic
complic
rare
aros
two
group
two
infant
pertussi
group
tabl
signific
differ
found
two
group
chest
radiograph
find
air
trap
peribronchi
thicken
consolid
laboratori
data
show
significantli
higher
absolut
wbc
lymphocyt
number
children
pertussi
infant
rsv
bronchiol
vs
cellsmm
p
vs
cellsmm
p
mannwhitney
u
test
final
children
pertussi
higher
absolut
blood
eosinophil
number
children
rsv
bronchiol
vs
cellsmm
p
signific
differ
report
absolut
neutrophil
number
absolut
platelet
number
hb
concentr
sgot
sgpt
ggt
crp
tabl
infant
pertussi
four
receiv
first
dtap
vaccin
dose
one
receiv
two
dose
control
group
infant
receiv
first
dtap
vaccin
dose
tabl
patient
test
posit
b
pertussi
alreadi
undergon
macrolid
antibiot
therapi
specimen
collect
specimen
collect
antibiot
therapi
receiv
antibiot
therapi
three
infant
pertussi
infect
coinfect
rsv
two
rhinoviru
differ
found
clinic
demograph
find
infant
b
pertussi
infect
alon
infant
b
pertussi
rsv
rv
coinfect
case
suspect
pertussi
confirm
molecular
analysi
b
pertussi
strain
isol
analyz
evalu
molecular
variant
particular
molecular
analysi
detect
allel
variant
tabl
b
pertussi
strain
cultiv
infant
enrol
alreadi
receiv
specif
antibiot
therapi
specimen
collect
technic
problem
aros
sampl
collect
retrospect
singlecent
studi
identifi
sever
demograph
clinic
laboratori
featur
might
help
diagnos
suspect
pertussi
infant
hospit
acut
respiratori
symptom
anoth
import
find
studi
b
pertussi
strain
circul
pediatr
emerg
depart
seem
differ
genet
current
use
dtap
vaccin
hospit
infant
enrol
studi
five
pertussi
four
bronchiol
alreadi
vaccin
itali
vaccin
schedul
provid
first
pertussi
vaccin
dose
age
month
booster
dose
month
age
find
confirm
previou
report
show
mani
children
pertussi
never
vaccin
pertussi
first
dose
first
two
dose
often
provid
scarc
protect
analyz
patient
demograph
data
line
other
found
children
whoop
cough
breastf
less
frequent
bronchiol
result
prevent
us
conjectur
whether
breast
feed
might
protect
risk
b
pertussi
infect
first
year
life
call
studi
assess
import
question
studi
confirm
clinic
data
help
diagnos
whoop
cough
diagnosi
infant
expect
hallmark
clinic
characterist
specif
pertussi
paroxysm
cough
studi
confirm
clinic
sign
suggest
b
pertussi
infect
episod
apnea
cyanosi
physic
examin
fever
absent
children
pertussi
common
patient
bronchiol
studi
sampl
chest
auscult
found
children
pertussi
abnorm
chest
sound
wherea
patient
control
group
rale
infant
hospit
suspect
b
pertussi
studi
clinic
featur
suggest
whoop
cough
diagnosi
addit
proof
might
come
laboratori
find
show
mark
lymphocytosi
anoth
distinct
find
significantli
higher
eosinophil
number
infant
pertussi
control
group
sinc
earli
research
question
role
b
pertussi
toxin
hypereosinophilia
respons
pertussi
hypothesi
await
confirmatori
data
studi
research
two
pertussi
isol
undertook
genet
molecular
analysi
investig
gene
variat
pertussi
toxin
gene
ptx
particular
subunit
ptxa
pertussi
toxin
gene
promot
ptxp
prn
univers
indic
character
molecular
featur
b
pertussi
catalyt
subunit
four
subunit
variant
describ
cultur
molecular
data
allow
us
identifi
strain
express
variant
wherea
pertussi
vaccin
contain
variant
pertactin
gene
polymorph
resid
region
call
mani
eleven
differ
prn
allel
identifi
acellular
pertussi
vaccin
contain
allel
two
infant
whose
aspir
suitabl
molecular
genet
analysi
rtpcr
identifi
gene
also
found
infant
european
countri
franc
finland
japan
also
found
strain
variant
pertussi
toxin
promot
variant
allow
bacteria
increas
toxin
product
sever
clinic
sign
symptom
manifest
unfortun
abl
analyz
b
pertussi
strain
two
infant
cultur
neg
infant
pcr
confirm
pertussi
alreadi
receiv
specif
antibiot
therapi
specimen
collect
technic
problem
aros
sampl
collect
without
seek
inform
indepth
molecular
genet
analysi
standard
protocol
say
whether
pertussi
strain
isol
two
patient
differ
immunolog
vaccin
variant
one
two
patient
month
old
month
old
neither
infant
vaccin
pertussi
receiv
macrolid
antibiot
treatment
time
collect
nasopharyng
aspir
specimen
equal
import
isol
contain
variant
known
highproduc
pertussi
toxin
variant
result
increas
virul
immun
suppress
reason
exclud
possibl
infant
might
manifest
diseas
even
vaccin
vaccineinduc
immun
would
immun
particular
strain
isol
median
age
onset
infant
hospit
pertussi
low
around
day
find
confirm
intern
evid
show
vaccin
strategi
envisag
addit
dose
birth
matern
immun
advis
prevent
diseas
first
six
month
life
accord
publish
data
assum
improv
surveil
diagnosi
would
allow
accur
epidemiolog
assess
pertussi
help
establish
better
vaccin
strategi
time
age
vaccin
limit
studi
small
number
infant
enrol
fact
could
analyz
b
pertussi
strain
two
patient
nasopharyng
wash
refer
standard
detect
b
pertussi
cultur
conclus
even
season
rsv
outbreak
differenti
diagnosi
bronchiol
especi
children
younger
one
year
consid
whoop
cough
absenc
exposur
ill
contact
local
epidemiolog
surveil
major
clinic
factor
diagnos
whoop
cough
typic
paroxysm
cough
lymphocytosi
increas
eosinophil
number
absent
abnorm
chest
sound
molecular
analysi
suggest
also
itali
b
pertussi
strain
differ
includ
current
vaccin
find
might
call
chang
current
pertussi
vaccin
accord
also
current
strategi
us
countri
includ
matern
immun
tdap
